Innovation Pharmaceuticals Inc (IPIX)

[GreenBioAnalyst]

This Brilacidin drug (As Bril we call it at ST) holds so much promise for SARs-CoV2. Just like its 3-in-action as an antiviral, anti-inflammatory, and antimicrobial, its potential application now gives it three shots on goal!

1. As a therapeutic stand-alone treatment (IV) and or/ prophylaxis for preventative if used as an oral pill.
2. As an adjunct or a combination drug with another antiviral drug, as cited by the fifth bullet point of the last pr; or,
3. As an adjuvant to a vaccine. I'm hoping that RBL gets this with what BARDA and JNJ are working on the discovery stage.

The other thing that I had discovered about Brilacidin's signaling pathway... it is not just one. It's actually two!
A. The IFN-b signaling pathway and
B. cAMP ARE THE TWO SIGNALING PATHWAYS THAT modulate the innate and adaptive immune response when it comes to viral infections and in addressing cytokine storm to induct its anti-inflammatory properties!

https://www.thermofisher.com/ca/en/home/life-science/cell-analysis/signaling-pathways/interferon/interferon-overview.html